Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Actionable Biomarkers in Lung Cancer: Clinical Applications for Nursing Practice
  • CE

Credits Available
Registered Nurses: 1.0 Nursing contact hour
Released: July 27, 2022 Expiration: July 26, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme
person default
Beth Sandy, MSN, CRNP
Elizabeth S. Waxman, BSN, MSN, ANP-BC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate new and emerging predictive biomarkers that guide precision treatment decisions in patients with NSCLC
  • Apply available clinical data and new therapeutic options for the individualized treatment of patients with actionable biomarkers
  • Discuss with patients the benefits and limitations of biomarker testing and targeted therapies, along with practical considerations such as comorbidities and adherence
  • Develop a proactive management plan for AEs associated with recently approved targeted agents and novel combinations

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.
Elizabeth S. Waxman, BSN, MSN, ANP-BC

Nurse Practitioner
Thoracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth S. Waxman, BSN, MSN, ANP-BC, has no relevant financial relationships to disclose.

Staff

Kelly Brandt, PharmD
Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncology nurses and other healthcare professionals who care for patients with lung cancer.

Goal

The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with lung cancer who have actionable biomarkers.

Accreditation

 

Joint Accreditation Statement

 

  

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 27, 2022, through July 26, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Actionable Biomarkers in Lung Cancer: Clinical Applications for Nursing Practice
  • CE

Loading...
In this on-demand webcast from a live program, expert Beth Sandy, MSN, CRNP, discusses the importance of biomarker testing in NSCLC and approved targeted therapies for actionable genomic alterations.
person default
Beth Sandy, MSN, CRNP
Elizabeth S. Waxman, BSN, MSN, ANP-BC
Registered Nurses: 1.0 Nursing contact hour
Released: July 27, 2022 Expiration: July 26, 2023

Related Content

Downloadable slideset from Antonio Urbina, MD, on HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Released: September 27, 2022

Antonio Urbina, MD, discusses HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 27, 2022 Expired: September 26, 2023

DESTINY-Lung02 interim analyses: efficacy/safety of 2 doses of T-DXd (5.4 mg/kg and 6.4 mg/kg) in patients with HER2-mutated NSCLC and at least 1 previous therapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 26, 2022

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Released: September 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings